Back

MYC-NFATC2 axis maintains cell cycle and mitochondrial function in AML cells

Patterson, S. D.; Massett, M. E.; Huang, X.; Jorgensen, H. G.; Michie, A. M.

2023-11-17 cancer biology
10.1101/2023.11.15.567209 bioRxiv
Show abstract

Acute myeloid leukaemia (AML) is a clonal haematological malignancy affecting the myeloid lineage with generally poor patient outcomes, owing to the lack of targeted therapies. The histone lysine demethylase 4A (KDM4A) has been established as a novel therapeutic target in AML, due to its selective oncogenic role within leukaemic cells. We identify that the transcription factor NFATC2 is a novel binding and transcriptional target of KDM4A in the human AML THP-1 cell line. Further, cytogenetically diverse AML cell lines, including THP-1, were dependent on NFATC2 for colony formation in vitro, highlighting a putative novel mechanism of AML oncogenesis. Our study demonstrates that NFATC2 maintenance of cell cycle progression in human AML cells was driven primarily by CCND1. Through RNA-seq and ChIP-seq, NFATC2 was shown to bind to the promoter region of genes involved in oxidative phosphorylation and subsequently regulate their gene expression in THP-1 cells. Furthermore, our data show that NFATC2 shares transcriptional targets with the transcription factor c-MYC, with MYC knockdown phenocopying NFATC2 knockdown. These data suggest a novel co-ordinated role for NFATC2 and MYC in the maintenance of THP-1 cell function, indicative of a potential means of therapeutic targeting in human AML. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=194 HEIGHT=200 SRC="FIGDIR/small/567209v1_ufig1.gif" ALT="Figure 1"> View larger version (50K): org.highwire.dtl.DTLVardef@10b4dc5org.highwire.dtl.DTLVardef@11ed9aaorg.highwire.dtl.DTLVardef@6457a9org.highwire.dtl.DTLVardef@1b722b4_HPS_FORMAT_FIGEXP M_FIG C_FIG Acute myeloid leukaemia (AML) cells of diverse cytogenetic backgrounds are dependent on NFATC2 for survival; in THP-1 cells, NFATC2 is downstream of the epigenetic regulator KDM4A. NFATC2 promotes G1/S phase transition in the cell cycle and oxidative phosphorylation. In addition, NFATC2 functions downstream of transcription factor MYC, and maintains CCND1 expression.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Oncogene
85 papers in training set
Top 0.1%
12.3%
2
Cell Death & Disease
126 papers in training set
Top 0.2%
7.2%
3
Molecular and Cellular Biology
47 papers in training set
Top 0.1%
6.6%
4
Oncogenesis
12 papers in training set
Top 0.1%
5.5%
5
Molecular Cancer Research
49 papers in training set
Top 0.1%
5.5%
6
Cancers
213 papers in training set
Top 1%
5.4%
7
eLife
5828 papers in training set
Top 22%
5.4%
8
iScience
1154 papers in training set
Top 5%
3.5%
50% of probability mass above
9
PLOS ONE
5266 papers in training set
Top 36%
3.4%
10
Frontiers in Immunology
638 papers in training set
Top 4%
3.2%
11
Life Science Alliance
285 papers in training set
Top 1%
3.1%
12
Scientific Reports
3612 papers in training set
Top 45%
2.4%
13
EMBO Reports
263 papers in training set
Top 3%
1.9%
14
Journal of Biological Chemistry
690 papers in training set
Top 5%
1.7%
15
Nucleic Acids Research
1281 papers in training set
Top 9%
1.7%
16
Leukemia
42 papers in training set
Top 0.5%
1.5%
17
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.4%
1.3%
18
Clinical Epigenetics
60 papers in training set
Top 0.4%
1.3%
19
Nature Communications
5641 papers in training set
Top 49%
1.3%
20
Science Advances
1243 papers in training set
Top 23%
1.3%
21
International Journal of Molecular Sciences
494 papers in training set
Top 12%
1.1%
22
Molecular Oncology
55 papers in training set
Top 1%
1.1%
23
Cells
249 papers in training set
Top 5%
1.1%
24
PLOS Pathogens
820 papers in training set
Top 8%
1.0%
25
Oncotarget
18 papers in training set
Top 0.4%
0.9%
26
Cell Death Discovery
58 papers in training set
Top 2%
0.8%
27
Epigenetics
50 papers in training set
Top 0.7%
0.8%
28
Clinical Cancer Research
64 papers in training set
Top 2%
0.8%
29
Cellular and Molecular Life Sciences
96 papers in training set
Top 2%
0.8%
30
Biochemical Journal
91 papers in training set
Top 2%
0.6%